genOway Improves its Growth With Major Japanese Biopharmaceutical Companies
News Jun 14, 2010
genOway announces strong growth of its business with major Japanese biopharmaceutical companies
The three Japanese biopharmaceutical companies, now customers of genOway, rank among the top ten of the nation’s biopharmaceutical industry. The amount of the active contracts just exceeded €400,000.
These agreements cover the development and delivery of genetically modified animal models and particularly humanized models dedicated to pharmaceutical compound testing. Other contractual details were not disclosed.
Alexandre Fraichard, CEO of genOway, declared: “Japanese biopharmaceutical industry is beginning to show signs of recovery. We were able to drop back on the market since the second half of 2009 and are very pleased that three of the largest Japanese biopharmaceutical companies now make use of our services and added value solutions. It is very important for us to attend sustainably this market, the second in size after the United States. In fact, we are very confident in signing several contracts in Japan in the coming trimesters.”
Drug Transport Gene May Explain Why Ovarian Cancer Patients React Differently to ChemotherapyNews
A gene which produces a protein that transports drugs in and out of cells may explain why some women treated with chemo have serious side effects.READ MORE
DETECTR Sniffs Out DNA Signals Using CRISPR-Cas9's CousinNews
A new technology allows amplification and detection of genomic snippets present in a sample, using the enzyme Cas12.READ MORE
SHERLOCK, the Paper-Based DNA Sleuth, Receives a Powerful UpgradeNews
SHERLOCK, a CRISPR-based test which allows detection of any genomic signals of interest, is now more portable and powerful.READ MORE